Siegfried has agreed to buy two drug product sites near Barcelona, Spain, from Novartis, in a deal expected to close by the end of 2020. Terms were not disclosed but Siegfried said that its sales should surpass CHF 1 billion in 2021, with the drug product operations “achieving the targeted critical size”.